Direct Oral Anticoagulants Is Fastest Growing Segment Fueling The Growth Of Anticoagulant Market
Anticoagulant Market |
Market Overview:
Anticoagulants, also known as blood thinners, help prevent blood clots from forming or getting bigger. They are used to treat and prevent conditions like blood clots (deep vein thrombosis, pulmonary embolism), irregular heartbeat (atrial fibrillation), heart attack, stroke and many others. Anticoagulants have advantages over other treatments as they are highly effective, usually do not require frequent monitoring and have minimal side effects.
Market key trends:
One of the key trends in the anticoagulant market is the increasing preference for direct oral anticoagulants (DOACs) over conventional anticoagulants such as warfarin. DOACs have emerged as substitute for warfarin owing to better safety profile, predictable pharmacological behavior with less drug and food interactions, rapid onset of action, and lack of need for monitoring. This has led to their increased adoption in medical practices around the world. Furthermore, patents expiration of blockbuster conventional anticoagulant drugs and robust pipeline of novel oral anticoagulants are some of the major factors expected to drive the growth of global anticoagulant market over the forecast period.
The global Anticoagulant Market Size is estimated to be valued at US$ 36,830.47 Mn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Segment Analysis
The global anticoagulant market is segmented on the basis of drug class, route of administration, application, distribution channel, and geography. By drug class, the market is segmented into NOACs, Heparin & LMWH, VKAs, and others. The NOACs segment dominates the market due to its easy administration, less monitoring requirements, and fewer dietary restrictions compared to VKAs.
Key Takeaways
The global anticoagulant market is expected to witness high growth, exhibiting a CAGR of 9.4% over the forecast period, due to increasing burden of cardiovascular diseases.
Regional analysis
North America dominates the anticoagulant market and is expected to continue its dominance over the forecast period. This is attributed to the growing demand for NOACs drugs and well-established healthcare infrastructure in the region. Asia Pacific exhibits the fastest growth due to increasing healthcare expenditure and rising geriatric population.
Key players
Key players operating in the anticoagulant market are Pfizer Inc., Sanofi SA, Dr. ReddyĆ¢€TMs Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma AS, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others. Pfizer Inc. dominates the anticoagulant drug market owing to its flagship NOAC drug—Eliquis. Read More: https://www.dailyprbulletin.com/the-growth-of-anticoagulant-market-size-and-share-analysis/
Comments
Post a Comment